GPC3-CAR T cells

GPC3-CAR T cells are an autologous cell therapy consisting of T lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting Glypican-3 (GPC3). GPC3 is a heparan sulfate proteoglycan that is highly expressed in hepatocellular carcinoma (HCC) but absent in healthy adult tissues, making it an ideal tumor-associated antigen. The CAR construct typically utilizes an anti-GPC3 single-chain variable fragment (scFv), often derived from the GC33 antibody, linked to intracellular signaling domains such as CD3ζ and costimulatory molecules like CD28 and 4-1BB. Fourth-generation (4G) iterations of these cells may include additional modifications to enhance cytokine production or metabolic fitness within the immunosuppressive tumor microenvironment. Developed by institutions including Zhongshan Hospital and Renji Hospital, this therapy is primarily investigated for advanced HCC, with administration routes including intravenous infusion and regional intra-arterial delivery via vascular interventional therapy.

Other names

GPC3-targeted CAR-T cellsGPC-3-targeted CAR-T cellsGPC 3-targeted CAR-T cellsfourth-generation GPC3-targeted autologous CAR-T cellsGPC3-targeted chimeric antigen receptor T cellsGPC-3-targeted chimeric antigen receptor T cellsGPC 3-targeted chimeric antigen receptor T cells